This study is looking at how a drug called azacitidine affects tumor-infiltrating lymphocytes (TILs) in people with high-risk, early-stage breast cancer. TILs are immune cells that fight cancer. You might be able to join if you are at least 18 years old, have good general health (ECOG 0, 1, or 2), and have early-stage invasive breast cancer that is considered high-risk, specifically triple-negative breast cancer. The main goal is to see if azacitidine changes the number of TILs in your tumor after two weeks of treatment. The study plans to enroll about 40 participants, but its current status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll about 40 participants.

What's involved

You would have screening procedures within 30 days of your first treatment, including medical history, physical exam, vital signs, and blood tests. The primary outcome is measured at 2 weeks from the first dose of azacitidine.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 2 weeks from the first dose of azacitidine. Longer-term follow-up is not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.